Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis.

Int J Rheum Dis · 2023 · PMC10092464 · PMID 36253032

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

3.3 Efficacy outcomes At study transition (week 0), week 72, and at the end of the study, the DAS28 (mean ± SD) scores were 2.22 ± 0.95, 2.10 ± 0.91, and 2.06 ± 0.89 respectively, indicating a decreasing trend against time after the study transition and continuing until the end of the study.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.